Related Experiment Video
Updated: May 6, 2026

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
Published on: September 28, 2019
Cross-talk of membrane lipids and Alzheimer-related proteins
Jochen Walter1, Gerhild van Echten-Deckert
1Department of Neurology, University of Bonn, Sigmund-Freud-Str, 25, 53127, Bonn, Germany. Jochen.Walter@ukb.uni-bonn.de.
Abstract:
Alzheimer's disease (AD) is neuropathologically characterized by the combined occurrence of extracellular β-amyloid plaques and intracellular neurofibrillary tangles in the brain. While plaques contain aggregated forms of the amyloid β-peptide (Aβ), tangles are formed by fibrillar forms of the microtubule associated protein tau. All mutations identified so far to cause familial forms of early onset AD (FAD) are localized close to or within the Aβ domain of the amyloid precursor protein (APP) or in the presenilin proteins that are essential components of a protease complex involved in the generation of Aβ. Mutations in the tau gene are not associated with FAD, but can cause other forms of dementia. The genetics of FAD together with biochemical and cell biological data, led to the formulation of the amyloid hypothesis, stating that accumulation and aggregation of Aβ is the primary event in the pathogenesis of AD, while tau might mediate its toxicity and neurodegeneration.The generation of Aβ involves sequential proteolytic cleavages of the amyloid precursor protein (APP) by enzymes called β-and γ-secretases. Notably, APP itself as well as the secretases are integral membrane proteins. Thus, it is very likely that membrane lipids are involved in the regulation of subcellular transport, activity, and metabolism of AD related proteins.Indeed, several studies indicate that membrane lipids, including cholesterol and sphingolipids (SLs) affect Aβ generation and aggregation. Interestingly, APP and other AD associated proteins, including β-and γ-secretases can, in turn, influence lipid metabolic pathways. Here, we review the close connection of cellular lipid metabolism and AD associated proteins and discuss potential mechanisms that could contribute to initiation and progression of AD.
Insights
Alzheimer's disease (AD) involves amyloid plaques and tau tangles. This review explores how cellular lipid metabolism, including cholesterol and sphingolipids, impacts AD protein interactions and disease progression.
Area of Science:
- Neuroscience
- Biochemistry
- Cell Biology
Background:
- Alzheimer's disease (AD) is characterized by amyloid plaques and neurofibrillary tangles.
- Familial early-onset AD mutations implicate amyloid precursor protein (APP) and presenilins in amyloid-beta (Aβ) generation.
- The amyloid hypothesis posits Aβ accumulation as the primary AD event.
Purpose of the Study:
- To review the intricate relationship between cellular lipid metabolism and AD-associated proteins.
- To discuss potential mechanisms linking lipid metabolism to AD initiation and progression.
Main Methods:
- Review of existing literature on AD pathogenesis, protein interactions, and lipid metabolism.
- Analysis of studies investigating the role of membrane lipids in Aβ generation and aggregation.
- Examination of reciprocal interactions between AD proteins and lipid metabolic pathways.
Main Results:
- Membrane lipids, including cholesterol and sphingolipids, influence Aβ generation and aggregation.
- APP and secretases (β- and γ-secretases) interact with and affect lipid metabolic pathways.
- AD proteins are integral membrane proteins, suggesting a crucial role for membrane lipids.
Conclusions:
- Cellular lipid metabolism is closely linked to AD-associated proteins.
- Lipid-protein interactions represent a significant area for understanding AD pathogenesis.
- Targeting lipid metabolism may offer novel therapeutic strategies for Alzheimer's disease.
More Related Videos
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Dementia l: Introduction
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Alzheimer's Disease: Treatment

